People: Hologic Inc (HOLX.O)

HOLX.O on Nasdaq

33.27USD
5 Feb 2016
Change (% chg)

$-1.94 (-5.51%)
Prev Close
$35.21
Open
$35.02
Day's High
$35.43
Day's Low
$33.16
Volume
3,326,146
Avg. Vol
2,629,920
52-wk High
$43.00
52-wk Low
$29.71

Search Stocks

Summary

Name Age Since Current Position

Stephen MacMillan

51 2015 Chairman of the Board, President, Chief Executive Officer

Robert McMahon

46 2014 Chief Financial Officer

Eric Compton

50 2014 Chief Operating Officer

Jay Stein

72 2008 Chairman Emeritus, Senior Vice President & Chief Technical Officer

Claus Egstrand

53 2014 Senior Vice President, General Manager - International

Allison Bebo

2015 Senior Vice President - Human Resources

John Griffin

2015 General Counsel

Elaine Ullian

67 2015 Lead Independent Director

Jonathan Christodoro

39 2013 Independent Director

Sally Crawford

61 2007 Independent Director

Scott Garrett

64 2013 Independent Director

Nancy Leaming

67 2003 Independent Director

Lawrence Levy

76 2005 Independent Director

Samuel Merksamer

35 2013 Independent Director

Christiana Stamoulis

44 2011 Independent Director

Wayne Wilson

66 2007 Independent Director

Al Kildani

Senior Director - Investor Relations

Biographies

Name Description

Stephen MacMillan

Mr. Stephen P. MacMillan is Chairman of the Board, President, Chief Executive Officer of the company. Mr. MacMillan was appointed as President, Chief Executive Officer and a director in December 2013. Prior to joining the Company, Mr. MacMillan served as the Chief Executive Officer of sBioMed, LLC, a biomedical research firm that produces infection control products, which he joined in October 2012. Prior to joining sBioMed, LLC, He served in various roles at Stryker Corporation, including as its Chief Operating Officer from June 2003 to December 2004, its President from June 2003 to February 2012, its Chief Executive Officer from January 2005 to February 2012 and its Chairman from January 2010 to February 2012. Mr. MacMillan began his career with Procter & Gamble in 1985 and later spent 11 years with Johnson & Johnson, where he served in various roles, including President of Johnson & Johnson’s consumer pharmaceuticals joint venture with Merck from December 1998 to December 1999. From March 2000 to March 2003, He served as Sector Vice President, Global Specialty Operations of Pharmacia Corporation, a global pharmaceutical company. Mr. MacMillan currently serves on the board of directors of Alere, Inc. Mr. MacMillan previously served on the board of directors of Texas Instruments Incorporated from 2008 to 2012. Mr. MacMillan holds a Bachelor of Arts degree in economics from Davidson College and is a graduate of the Harvard Business School’s Advanced Management Program. As our President and Chief Executive Officer, Mr. MacMillan has direct responsibility for the Company’s strategy and operations. This position, together with his many years of experience in the healthcare industry, make him an invaluable contributor to the Board.

Robert McMahon

Mr. Robert W. McMahon has been appointed as Chief Financial Officer of the Company effective May 26, 2014. Robert W. McMahon is a proven business executive with a demonstrated track record of success. An industry veteran with more than 20 years of healthcare finance experience, Mr. McMahon worked at Johnson & Johnson from 1993 to 2014, in executive finance roles of increasing responsibility. Most recently, he served as the Worldwide Vice President, Finance and Business Development, Ortho Clinical Diagnostics for Johnson & Johnson. In this position, he was responsible for the financial leadership and oversight of a $1.9 billion business. From 2006 to 2011, he served as Vice President, Finance, Consumer Group and from 2004 to 2006 he served as Vice President, Finance, Networking & Computing Services. He is a Certified Management Accountant and holds a Masters of Business Administration from the University of Central Florida and a Bachelor of Science in Business Administration from the University of Florida.

Eric Compton

Mr. Eric Compton has been appointed as Chief Operating Officer of the Company effective April 14, 2014. Eric Compton is a proven business executive with a track record of success in medical devices, diagnostics, start-ups, joint ventures, and business turnarounds at both Johnson & Johnson and Procter & Gamble. An entrepreneurial leader with almost 30 years of experience, Mr. Compton worked at Johnson & Johnson from 1995 to 2014, in roles of increasing responsibility. Most recently, he served as the Worldwide President, Ortho Clinical Diagnostics for Johnson & Johnson. In this position, he was accountable for over $2.0 billion in global sales across multiple disciplines and held direct responsibility for a workforce of more than 2,800 individuals. From 2011 to August 2012, he served as the General Manager, Ortho Clinical Diagnostics and from 2009 to 2011 he served as Worldwide Vice President, Franchise Strategic Marketing, Diabetes Care. He served in various sales and marketing leadership roles at Johnson & Johnson earlier in his career. Prior to joining Johnson & Johnson, Mr. Compton was a Business Development Manager at Procter & Gamble. He started his career in 1986 at Procter & Gamble as a Sales Representative. Mr. Compton is a member of the Board of Delaware Valley College and AdvaMed DX. He holds a Masters of Business Administration from Kennesaw State University and a Bachelor of Arts from the University of Richmond.

Jay Stein

Dr. Jay A. Stein is Chairman Emeritus, Senior Vice President and Chief Technical Officer of Hologic Inc. Dr. Stein, a co-founder, Chairman Emeritus, Senior Vice President and the Chief Technical Officer of our Company, has served as Executive or Senior Vice President and Chief Technical Officer of the Company since its organization in October 1985. Since October 2007, Dr. Stein has served as Chairman Emeritus pursuant to which he continues to participate in meetings of the Board. He served as one of our directors from October 1985 through October 2007, including as Chairman of our Board from June 2001 to November 2002. Dr. Stein received a Ph.D. in Physics from The Massachusetts Institute of Technology. He is the principal author of numerous patents involving X-ray technology.

Claus Egstrand

Mr. Claus Egstrand has been named Senior Vice President, General Manager - International of the Company effective April 14, 2014. Claus Egstrand is a senior executive with a proven global track record of delivering strong results and achieving sustainable top and bottom line business growth across geographies, while strengthening organizations, cultures and talent. Mr. Egstrand has spent the majority of his 30-plus year career in the life sciences and business services industries, focusing on driving executional improvement across global operations. Most recently, Mr. Egstrand was the Leader of Consumer Healthcare, Europe for Merck & Co., Inc., where he was responsible for a plan for growth, including sales and marketing, in developed and developing markets. Before joining Merck in 2012, Mr. Egstrand was the Chief Marketing Officer of Regus plc, a provider of flexible office solutions. From 2006 to 2011, He was the Vice President, Chief Marketing Officer, EMEA (Europe, Middle East and Africa), and General Manager Medsurg, Europe, for Stryker Corporation. His prior experience was in senior international and regional roles at Pfizer Consumer Healthcare, Pharmacia Corporation, and Johnson & Johnson/Merck Pharmaceuticals. He began his career in 1982 in sales and marketing at Farma Ltd. Mr. Egstrand holds a Masters of Business Administration from the University of Copenhagen and an undergraduate business degree from Niels Brock, Copenhagen Business College.

Allison Bebo

Ms. Allison Bebo has been appointed as Senior Vice President - Human Resources of the Company effective February 2, 2015. She is a proven business leader with extensive human resources experience and a demonstrated track record of delivering results. She worked for ANN INC. for 20 years in positions of increasing responsibility, mainly in talent management and organizational development. Most recently she served as vice president, talent management. In this position, she was responsible for enterprise-wide talent management and workplace engagement strategies. She has a BA in political science from the University of California, Los Angeles .

John Griffin

Mr. John Griffin has been appointed as General Counsel of the Company effective February 2, 2015. Mr. Griffin is a seasoned executive with nearly 30 years of experience across a broad spectrum of legal matters. He spent 15 years in positions of increasing responsibility at Covidien, most recently serving as vice president and deputy general counsel, where he managed all litigation matters and compliance programs. Before joining Covidien, he served as an assistant US attorney for the District of Massachusetts . He began his legal career at Nutter, McClennen & Fish in Boston. He has a JD from Harvard Law School and a BA in political science from Columbia University .

Elaine Ullian

Ms. Elaine S. Ullian is an Lead Independent Director of the Company. She was an Independent Director of Hologic Inc. Ms. Ullian has been one of our directors since October 2007. Ms. Ullian served as President and Chief Executive Officer of Boston Medical Center, the successor of Boston University Medical Center Hospital, from 1996 until her retirement in January 2010. In April 1994, She was appointed President and Chief Executive Officer of Boston University Medical Center Hospital. From January 1987 to March 1994, She llian held the position of President and Chief Executive Officer of Faulkner Corporation/Faulkner Hospital. She holds two academic appointments: Associate Professor at Boston University School of Medicine and lecturer at Harvard University School of Public Health. Ms. Ullian also serves as a director of Vertex Pharmaceuticals Incorporated and Thermo Fisher Scientific Inc. She previously served as one of our directors from 1996 to 2003 and served as a director of Valeant Pharmaceuticals International, Inc. from 2004 to 2008. As former Chief Executive Officer of three hospitals, including two major academic medical centers, She brings knowledge and understanding of Hologic’s customer base, as well as their priorities and challenges. All three institutions led by Ms. Ullian over a 25 year period had a strong commitment to accessible health care, and a particular focus on women’s health services. As a person whose career had been dedicated to the provision of clinical care services to patients, she brings an important perspective to the Board.

Jonathan Christodoro

Mr. Jonathan Christodoro is Independent Director of the company. Mr. Christodoro became one of our directors in December 2013. Mr. Christodoro has served as a Managing Director of Icahn Capital LP, the entity through which Carl C. Icahn manages investment funds, since July 2012. He is responsible for identifying, analyzing and monitoring investment opportunities and portfolio companies for Icahn Capital. Prior to joining Icahn Capital LP, He served in various investment and research roles at P2 Capital Partners, LLC, Prentice Capital Management, LP and S.A.C Capital Advisors, LP. He began his career as an investment banking analyst at Morgan Stanley, where he focused on merger and acquisition transactions across a variety of industries. He currently also serves on the boards of directors of Enzon Pharmaceuticals, Inc. and Herbalife Ltd. Carl C. Icahn has a non-controlling interest in Herbalife through the ownership of securities. He received an M.B.A from the University of Pennsylvania’s Wharton School of Business with Distinction, majoring in Finance and Entrepreneurial Management. Mr. Christodoro received a B.S. in Applied Economics and Management Magna Cum Laude with Honors Distinction in Research from Cornell University. Mr. Christodoro also served in the United States Marine Corps. He was selected as a member of the Board pursuant to the Standstill Agreement with the Icahn Group. It is anticipated that his financial, strategic and investment banking background and experience, as well as his relationship with the Icahn Group, and its interests as one of the more significant beneficial owners of our stock, will bring valuable perspectives to the Board.

Sally Crawford

Ms. Sally W. Crawford is an Independent Director of Hologic Inc. Ms. Crawford became one of our directors effective upon our merger with Cytyc Corporation (“Cytyc”) in October 2007, having previously served as a director of Cytyc since January 1998. From April 1985 until January 1997, She served as Chief Operating Officer of Healthsource, Inc., a publicly held managed care organization headquartered in New Hampshire. During her tenure at Healthsource, Inc., She held a variety of positions and responsibilities, including leading that company’s Northern Region operations and marketing efforts. Since January 1997, She has been a healthcare consultant in New Hampshire. She serves as a director of Universal American Corporation, Exact Sciences Corporation, Zalicus, Inc. and Insulet Corporation. Ms. Crawford served as a director of Chittenden Corporation from 1998 to 2008. Ms. Crawford’s service in various senior executive positions in the managed care sector and her continuing healthcare consulting practice contribute to her significant management and leadership experience and expertise in operational, regulatory and related disciplines applicable to our business and operations.

Scott Garrett

Mr. Scott T. Garrett has been appointed as Independent Director of Hologic, Inc. Mr. Garrett became one of our directors in May 2013. Mr. Garrett is currently an Operating Partner at Water Street Healthcare Partners. Mr. Garrett joined Water Street in 2011 after approximately 35 years in the global healthcare industry. Prior to joining Water Street, He served as Chairman, President and Chief Executive Officer of Beckman Coulter, a leading biomedical company, from 2008 to 2011. He joined Beckman Coulter in 2002 as President, Clinical Diagnostics Division. Prior to that, Mr. Garrett served as Vice Chairman and Interim Chief Executive Officer of Kendro Laboratory Products from 1999 to 2001. From 1994 to 1998, He served as Chairman, President and Chief Executive Officer of Dade Behring, a leading diagnostics company. He began his career at American Hospital Supply Corporation and continued there after that company was acquired by Baxter International, ultimately serving as Chief Executive of Baxter’s global laboratory business, Baxter Diagnostics. Mr. Garrett received a B.S. in Mechanical Engineering from Valparaiso University and a M.B.A. from Lake Forest Graduate School of Management. He currently also serves on the boards of directors of Immucor, Inc., MarketLab Inc., and AdvaMedDx. Mr. Garrett’s experience as the Chief Executive Officer and in other senior leadership positions with leading biomedical and diagnostics companies enables him to bring an operational perspective as well as valuable insights and experience to the Board.

Nancy Leaming

Ms. Nancy L. Leaming is an Independent Director of Hologic Inc. Ms. Leaming has been one of our directors since September 2003. Ms. Leaming, an independent consultant, was the Chief Executive Officer and President of Tufts Health Plan, a provider of healthcare insurance, from 2003 to 2005. Prior to that, She served as Tufts Health Plan’s President and Chief Operating Officer from 1998 to 2003, the Chief Operating Officer from 1995 to 1998 and the Chief Operating Officer/Chief Financial Officer from 1986 to 1995. Ms. Leaming currently serves on the boards of directors of Edgewater Technology, Inc. and Biogen Idec, Inc. Ms. Leaming’s leadership skills, financial acumen and her valuable insights into the healthcare reimbursement and payor market, where she spent 20 years in senior operational, financial and managerial roles, make her a valuable contributor to the Board.

Lawrence Levy

Mr. Lawrence M. Levy is an Independent Director of Hologic Inc. Mr. Levy has been one of our directors since December 2005. He retired from the position of Senior Counsel at Brown Rudnick LLP, an international law firm, in January 2011. He had been Senior Counsel at Brown Rudnick since February 2005 and, for more than 30 years before that had been a Partner at the firm, specializing in Corporate and Securities Law. Mr. Levy served as our Secretary from our formation in 1985 until December 2005. He is also a director of Option N.V. of Belgium, Scivanta Medical Corporation and the Facing History and Ourselves National Foundation. He received a B.A. from Yale University and a LLB from Harvard Law School. He is a seasoned corporate attorney with extensive experience in representing public and private companies in the United States and abroad. He chaired Brown Rudnick’s International Practice Group and, in 1997, opened Brown Rudnick’s London office, dividing his time between the firm’s London and Boston offices for more than 13 years. Mr. Levy’s broad legal and cross-border transactional experience enables him to provide valuable insights and perspectives to the Board.

Samuel Merksamer

Mr. Samuel J. Merksamer is Independent Director of the company. Mr. Merksamer became one of our directors in December 2013. He is a Managing Director of Icahn Capital LP, the entity through which Carl C. Icahn manages investment funds, where he has been employed since May 2008. He currently also serves on the boards of directors of Transocean Ltd., CVR Refining GP, LLC (the general partner of CVR Refining, LP), Navistar International Corporation, Ferrous Resources Limited, and CVR Energy, Inc. He was previously a director of: American Railcar Industries, Inc., from June 2011 to June 2013; Viskase Companies, Inc., from January 2010 to April 2013; PSC Metals Inc., from March 2009 to October 2012; Dynegy Inc., from March 2011 to September 2012; and Federal - Mogul Corporation, from September 2010 to January 2014. CVR Refining, CVR Energy, Federal — Mogul, American Railcar Industries, Viskase Companies and PSC Metals are each indirectly controlled by Carl C. Icahn. Mr. Icahn also has a non-controlling interest in Transocean, Navistar, Ferrous Resources and Dynegy Inc. through the ownership of securities. He received an A.B. in Economics from Cornell University in 2002. Mr. Merksamer was selected as a member of the Board pursuant to the Standstill Agreement with the Icahn Group. It is anticipated that his financial, strategic and investment banking background and experience, as well as his relationship with the Icahn Group, and its interests as one of the more significant beneficial owners of our stock, will bring valuable perspectives to the Board.

Christiana Stamoulis

Ms. Christiana Stamoulis serves as an Independent Director of Hologic, Inc. Ms. Stamoulis has been one of our directors since November 1, 2011. Ms. Stamoulis served as Senior Vice President of Corporate Strategy and Business Development at Vertex Pharmaceuticals Incorporated until August 2013. Ms. Stamoulis joined Vertex in 2009 with approximately 15 years of experience in the investment banking and management consulting industries where she advised global pharmaceutical and biotechnology companies on strategic and corporate finance decisions. Prior to joining Vertex, she was a Managing Director in the Investment Banking division of Citigroup from 2006 to 2009 where she led the building of the firm’s U.S. Life Sciences investment banking practice. Prior to her role at Citigroup, she was at Goldman, Sachs & Co. where she spent the majority of her investment banking career. Ms. Stamoulis started her career as a strategy consultant at The Boston Consulting Group. She holds a Bachelor of Science degree in Economics and a Bachelor of Science degree in Architecture from the Massachusetts Institute of Technology (MIT). Additionally, she holds a Master of Business Administration from the MIT Sloan School of Management where she focused on Applied Economics and Finance. Ms. Stamoulis’s solid foundation in strategic development coupled with extensive experience in executing initiatives for growth in the medical products field and related industries enable her to provide valuable insights to the Board.

Wayne Wilson

Mr. Wayne Wilson is an Independent Director of Hologic Inc. Mr. Wilson became one of our directors effective upon our merger with Cytyc in October 2007, having previously served as a director of Cytyc since 2003. He has been an independent business advisor since 2002. From 1995 to 2002, He served in various roles, including as President, Chief Operating Officer, and Chief Financial Officer, at PC Connection, Inc., a Fortune 1000, direct marketer of information technology products and services. From 1986 to 1995, he was a partner in the assurance and advisory services practice of Deloitte & Touche LLP. He also serves as a director of ARIAD Pharmaceuticals, Inc., Edgewater Technology, Inc. and FairPoint Communications, Inc. Mr. Wilson’s qualifications to serve on the Board include his extensive experience in financial accounting and reporting and his ability to evaluate financial results and generally oversee the financial reporting process of a publicly traded corporation.

Al Kildani

Search Stocks